{
    "clinical_study": {
        "@rank": "23338", 
        "acronym": "Spruce", 
        "arm_group": [
            {
                "arm_group_label": "OGX-427", 
                "arm_group_type": "Experimental", 
                "description": "Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1.  Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase.  The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Three loading doses of placebo will be administered IV Days -9 to -1. Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II study will compare the efficacy and safety of the combination of\n      carboplatin and pemetrexed with and without OGX-427 in patients with previously untreated\n      advanced non-squamous NSCLC."
        }, 
        "brief_title": "Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Squamous Non Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologic or cytologic diagnosis of advanced NSCLC, excluding squamous cell and\n             small cell histology.  Tumors with mixed NSCLC histologies are eligible, as long as\n             the predominant histology is not squamous.  If small-cell elements are present or not\n             otherwise specified histologically, the patient is not eligible.\n\n          2. Recurrent or Stage IV disease (according to American Joint Committee on Cancer (AJCC)\n             staging system, v7.0).\n\n          3. No prior systemic chemotherapy, immunotherapy, targeted therapy, or biological\n             therapy; adjuvant therapy is allowed as long as the interval from end of adjuvant\n             therapy until disease progression was >12 months.\n\n          4. No prior radiation therapy to the whole pelvis or to \u226525% of the total bone marrow\n             area.  Radiation therapy must be completed at least 2 weeks prior to randomization.\n             Must have recovered from acute adverse effects prior to randomization.\n\n          5. At least one measurable lesion according to Response Evaluation Criteria in Solid\n             Tumors (RECIST) v1.1.\n\n          6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.\n\n          7. Baseline laboratory values as follows:\n\n               -  Absolute neutrophil count (ANC) \u22651500/\u03bcL\n\n               -  Hemoglobin (Hgb) \u226510 g/dL\n\n               -  Platelets \u2265100,000/\u03bcL\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), \u22643.0 x the\n                  upper limit of normal (ULN); 5 x ULN if known hepatic metastases.\n\n               -  Total bilirubin \u22641.5 x ULN, unless secondary to Gilbert's disease\n\n               -  Serum creatinine \u22641.5 x ULN.  If creatinine is >1.5, calculate creatinine\n                  clearance (CrCl) \u226545 mL/min by the Cockcroft-Gault method:\n\n             Glomerular Filtration Rate (GFR) = (140-age) x (weight/kg) x (0.85 if female) (72 x\n             serum creatinine mg/dL)\n\n          8. Fertile male patients willing to use adequate contraceptive measures.\n\n          9. Female patients who are not of child-bearing potential, and fertile female patients\n             of child-bearing potential who agree to use adequate contraceptive measures, who are\n             not breastfeeding, and who have a negative serum or urine pregnancy test within 72\n             hours prior to start of randomization.\n\n         10. Life expectancy \u2265 12 weeks.\n\n         11. Must be \u226518 years of age at the time of consent.\n\n         12. Willingness and ability to comply with trial and follow-up procedures.\n\n         13. Ability to understand the nature of this trial and give written informed consent.\n\n        Exclusion Criteria:\n\n          1. Known anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor\n             receptor (EGFR) \"activating\" mutations where first-line treatment with targeted\n             tyrosine kinase inhibitor therapy is more appropriate.\n\n          2. Known central nervous system (CNS) disease other than neurologically stable, treated\n             brain metastases - defined as metastasis having no evidence of progression or\n             hemorrhage after treatment and no ongoing requirements for corticosteroids, (e.g.,\n             dexamethasone) for at least 2 weeks.\n\n          3. Any of the following cardiac diseases currently or within the last 6 months as\n             defined by New York Heart Association (NYHA) \u2265 Class 2:\n\n               -  Unstable angina pectoris\n\n               -  Congestive heart failure\n\n               -  Acute myocardial infarction\n\n               -  Conduction abnormality not controlled with pacemaker or medication\n\n               -  Significant ventricular or supraventricular arrhythmias (Patients with chronic\n                  rate-controlled atrial fibrillation in the absence of other cardiac\n                  abnormalities are eligible).\n\n          4. Patients currently receiving therapeutic anticoagulation.\n\n          5. Pregnant or lactating women.\n\n          6. Any serious, active underlying medical condition that would impair the ability of the\n             patient to receive study treatment, such as diabetes mellitus or infection.\n\n          7. Unable or unwilling to take folic acid or vitamin B12.\n\n          8. Active second malignancy (except non-melanomatous skin or superficial bladder cancer)\n             defined as requiring current need for cancer therapy or at high risk of recurrence\n             (>350%) during the study.\n\n          9. Psychological, familial, sociological, or geographical conditions that do not permit\n             compliance with the protocol.\n\n         10. Inability or unwillingness to comply with trial and/or follow-up procedures outlined\n             in the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "155", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829113", 
            "org_study_id": "SCRI LUN 229"
        }, 
        "intervention": [
            {
                "arm_group_label": "OGX-427", 
                "description": "Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1.\nFollowing the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. OGX-427 will be given prior to the administration of pemetrexed (500mg/m2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle.  A maximum of four treatment cycles will be administered.\nPatients with objective response or stable disease after four cycles of therapy will move on to a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle plus pemetrexed (500mg/m2 IV on Day 1).  Patients may remain on maintenance as long as they are benefiting and have no evidence of disease progression.", 
                "intervention_name": "OGX-427", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Three loading doses of placebo will be administered IV Days -9 to -1.\nFollowing the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. Placebo will be given prior to the administration of pemetrexed (500mg/m2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle. A maximum of four treatment cycles will be administered.\nPatients with objective response or stable disease after four cycles of therapy will move on to a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle plus pemetrexed (500mg/m2 IV on Day 1). Patients may remain on maintenance as long as they are benefiting and have no evidence of disease progression.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Recurrent Lung Cancer", 
            "Stage IV Lung Cancer", 
            "OGX-427", 
            "Sarah Cannon Research Institute", 
            "SCRI", 
            "OncoGenex", 
            "NSCLC", 
            "Non Small Cell Lung Cancer"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Rocky Mountain Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ft. Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33916"
                    }, 
                    "name": "Florida Cancer Specialists-South"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32804"
                    }, 
                    "name": "Florida Hospital Cancer Insitute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33705"
                    }, 
                    "name": "Florida Cancer Specialists-North"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40207"
                    }, 
                    "name": "Baptist Hospital East"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20817"
                    }, 
                    "name": "Center for Cancer and Blood Disorders"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64132"
                    }, 
                    "name": "Research Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68114"
                    }, 
                    "name": "Nebraska Methodist Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07932"
                    }, 
                    "name": "Hematology-Oncology Associates of Northern NJ"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Oncology Hematology Care, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29210"
                    }, 
                    "name": "South Carolina Oncology Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }, 
                    "name": "Tennessee Oncology - Chattanooga"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "AskSARAH@scresearch.net", 
                    "last_name": "AskSARAH"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology"
                }, 
                "investigator": {
                    "last_name": "David R. Spigel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "The Center for Cancer and Blood Disorders"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newport News", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23601"
                    }, 
                    "name": "Peninsula Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23230"
                    }, 
                    "name": "Virginia Cancer Institute"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed With or Without OGX-427 in Patients With Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (The Spruce Clinical Trial)", 
        "other_outcome": [
            {
                "description": "To evaluate the effect of treatment with OGX-427 on serum Hsp27 levels", 
                "measure": "Serum levels of Hsp27", 
                "safety_issue": "No", 
                "time_frame": "Every cycle (3 weeks)"
            }, 
            {
                "description": "To evaluate the correlation of biomarkers from archived tissue samples with clinical outcomes by assessing protein expression and a panel of genes utilizing an assay", 
                "measure": "Biomarkers in Archival Tissue", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "overall_contact": {
            "email": "asksarah@scresearch.net", 
            "last_name": "Sarah Cannon Research Institute (SCRI)", 
            "phone": "877-691-7274"
        }, 
        "overall_official": {
            "affiliation": "SCRI", 
            "last_name": "David R. Spigel, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine whether OGX-427 plus carboplatin/pemetrexed therapy shows a progression-free survival advantage versus carboplatin/pemetrexed", 
            "measure": "Progression-Free Survival", 
            "safety_issue": "No", 
            "time_frame": "Every 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829113"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare overall response rate in each treatment arm", 
                "measure": "Overall Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks"
            }, 
            {
                "description": "To compare the safety/toxicity of the combination of OGX-427 with carboplatin/pemetrexed versus placebo with carboplatin/pemetrexed. Treatment related toxicities will be assessed using Common Terminology Criteria for Adverse Events v4.0", 
                "measure": "Safety of the regimen", 
                "safety_issue": "Yes", 
                "time_frame": "Continuous review"
            }, 
            {
                "description": "To compare overall survival in each treatment arm", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Time from randomization until death"
            }
        ], 
        "source": "SCRI Development Innovations, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "OncoGenex Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "SCRI Development Innovations, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}